Tags

Type your tag names separated by a space and hit enter

Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration.
Stem Cells Transl Med. 2019 05; 8(5):466-477.SC

Abstract

Retinal cell therapy can have the objectives of rescue (i.e., modulation of metabolic abnormalities primarily for sight preservation) as well as replacement (i.e., replace cells lost due to injury or disease for sight restoration as well as preservation). The first clinical trials of retinal pigment epithelium (RPE) transplantation for vision-threatening complications of age-related macular degeneration (AMD) have begun with some preliminary signs of success (e.g., improvement in vision in some patients, anatomic evidence of transplant-host integration with some evidence of host photoreceptor recovery, long-term survival of autologous induced pluripotent stem cell-derived RPE transplants without immune suppression) as well as limitations (e.g., limited RPE suspension survival in the AMD eye, limited tolerance for long-term systemic immune suppression in elderly patients, suggestion of uncontrolled cell proliferation in the vitreous cavity). RPE survival on aged and AMD Bruch's membrane can be improved with chemical treatment, which may enhance the efficacy of RPE suspension transplants in AMD patients. Retinal detachment, currently used to deliver transplanted RPE cells to the subretinal space, induces disjunction of the first synapse in the visual pathway: the photoreceptor-bipolar synapse. This synaptic change occurs even in areas of attached retina near the locus of detachment. Synaptic disjunction and photoreceptor apoptosis associated with retinal detachment can be reduced with Rho kinase inhibitors. Addition of Rho kinase inhibitors may improve retinal function and photoreceptor survival after subretinal delivery of cells either in suspension or on scaffolds.

Authors+Show Affiliations

Institute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.Institute of Ophthalmology and Visual Science, Rutgers-New Jersey Medical School, Rutgers University, Newark, New Jersey, USA.Department of Pharmacology, Physiology, and Neuroscience, Rutgers-New Jersey Medical School, Newark, New Jersey, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

30748126

Citation

Zarbin, Marco, et al. "Concise Review: Update On Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration." Stem Cells Translational Medicine, vol. 8, no. 5, 2019, pp. 466-477.
Zarbin M, Sugino I, Townes-Anderson E. Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. Stem Cells Transl Med. 2019;8(5):466-477.
Zarbin, M., Sugino, I., & Townes-Anderson, E. (2019). Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. Stem Cells Translational Medicine, 8(5), 466-477. https://doi.org/10.1002/sctm.18-0282
Zarbin M, Sugino I, Townes-Anderson E. Concise Review: Update On Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. Stem Cells Transl Med. 2019;8(5):466-477. PubMed PMID: 30748126.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Concise Review: Update on Retinal Pigment Epithelium Transplantation for Age-Related Macular Degeneration. AU - Zarbin,Marco, AU - Sugino,Ilene, AU - Townes-Anderson,Ellen, Y1 - 2019/02/12/ PY - 2018/12/05/received PY - 2019/01/15/accepted PY - 2019/2/13/pubmed PY - 2020/5/1/medline PY - 2019/2/13/entrez KW - Autologous stem cell transplantation KW - Cell transplantation KW - Clinical trials KW - Embryonic stem cells KW - Experimental models KW - Induced pluripotent stem cells KW - Retina SP - 466 EP - 477 JF - Stem cells translational medicine JO - Stem Cells Transl Med VL - 8 IS - 5 N2 - Retinal cell therapy can have the objectives of rescue (i.e., modulation of metabolic abnormalities primarily for sight preservation) as well as replacement (i.e., replace cells lost due to injury or disease for sight restoration as well as preservation). The first clinical trials of retinal pigment epithelium (RPE) transplantation for vision-threatening complications of age-related macular degeneration (AMD) have begun with some preliminary signs of success (e.g., improvement in vision in some patients, anatomic evidence of transplant-host integration with some evidence of host photoreceptor recovery, long-term survival of autologous induced pluripotent stem cell-derived RPE transplants without immune suppression) as well as limitations (e.g., limited RPE suspension survival in the AMD eye, limited tolerance for long-term systemic immune suppression in elderly patients, suggestion of uncontrolled cell proliferation in the vitreous cavity). RPE survival on aged and AMD Bruch's membrane can be improved with chemical treatment, which may enhance the efficacy of RPE suspension transplants in AMD patients. Retinal detachment, currently used to deliver transplanted RPE cells to the subretinal space, induces disjunction of the first synapse in the visual pathway: the photoreceptor-bipolar synapse. This synaptic change occurs even in areas of attached retina near the locus of detachment. Synaptic disjunction and photoreceptor apoptosis associated with retinal detachment can be reduced with Rho kinase inhibitors. Addition of Rho kinase inhibitors may improve retinal function and photoreceptor survival after subretinal delivery of cells either in suspension or on scaffolds. SN - 2157-6580 UR - https://www.unboundmedicine.com/medline/citation/30748126/Concise_Review:_Update_on_Retinal_Pigment_Epithelium_Transplantation_for_Age_Related_Macular_Degeneration_ L2 - https://doi.org/10.1002/sctm.18-0282 DB - PRIME DP - Unbound Medicine ER -